Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/Matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart

Hypertension

Volumn 63, Issue 3, 2014, Pages

  Lauer, Dilyara ^a   Slavic, Svetlana ^a,b   Sommerfeld, Manuela ^a   Thöne Reineke, Christa ^a   Sharkovska, Yuliya ^a   Hallberg, Anders ^c   Dahlöf, Bjorn ^d   Kintscher, Ulrich ^a   Unger, Thomas ^a,e   Steckelings, Ulrike Muscha ^a,f   Kaschina, Elena ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UPPSALA UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

matrix metalloproteinase 9; myocardial infarction; receptor, angiotensin, type 2; TIMP1 protein, human

Indexed keywords

MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; RECEPTOR, ANGIOTENSIN, TYPE 2; TIMP1 PROTEIN, HUMAN;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GENE EXPRESSION REGULATION; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84894417555     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02522     Document Type: Article

References (36)

1. Tamargo J, López-Sendón J. Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov. 2011;10:536-555.
2. McKelvie RS, Benedict CR, Yusuf S. Evidence based cardiology: Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. BMJ. 1999;318:1400-1402.
3. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-Angiotensin systems. Physiol Rev. 2006;86:747-803.
4. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994;89:2273-2282.
5. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet. 2003;362:777-781.
6. Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens. 2010; 28(Suppl 1):50-55.
7. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:46-54.
8. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Moriguchi Y, Shibasaki Y, Kamihata H, Inada M, Iwasaka T. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998;83:1035-1046.
9. Callera G, Tostes R, Savoia C, Muscara MN, Touyz RM. Vasoactive peptides in cardiovascular (patho)physiology. Expert Rev Cardiovasc Ther. 2007;5:531-552.
10. Yang Z, Bove CM, French BA, Epstein FH, Berr SS, DiMaria JM, Gibson JJ, Carey RM, Kramer CM. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation. 2002;106:106-111.
11. Oishi Y, Ozono R, Yano Y, Teranishi Y, Akishita M, Horiuchi M, Oshima T, Kambe M. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension. 2003;41(3 Pt 2):814-818.
12. Kuizinga MC, Smits JF, Arends JW, Daemen MJAP. AT2 receptor blockade reduces cardiac interstitial cell DNA synthesis and cardiac function after rat myocardial infarction. J Mol Cell Cardiol. 1998;30:425-434.
13. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008.
14. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahloddddf B, Unger T. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol. 2011;11:187-192.
15. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-Angiotensin system in myocardial infarction?. Circulation. 2008;118:2523-2532.
16. Paulis L, Becker ST, Lucht K, Schwengel K, Slavic S, Kaschina E, Thoddddne-Reineke C, Dahloddddf B, Baulmann J, Unger T, Steckelings UM. Direct AT2 receptor stimulation in L-NAME-induced hypertension: The effect on pulse wave velocity and aortic remodeling. Hypertension. 2012;59:485-492.
17. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291-299.
18. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: Focus on renal damage. J Hypertens. 2009;27:2444-2451.
19. Slavic S, Lauer D, Sommerfeld M, Kemnitz UR, Grzesiak A, Trappiel M, Thoddddne-Reineke C, Baulmann J, Paulis L, Kappert K, Kintscher U, Unger T, Kaschina E. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J Mol Med (Berl). 2013;91:811-823.
20. Agocha AE, Eghbali-Webb M. A simple method for preparation of cultured cardiac fibroblasts from adult human ventricular tissue. Mol Cell Biochem. 1997;172:195-198.
21. McElmurray JH 3rd, Mukherjee R, New RB, Sampson AC, King MK, Hendrick JW, Goldberg A, Peterson TJ, Hallak H, Zile MR, Spinale FG. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999;291:799-811.
22. Vosgerau U, Lauer D, Unger T, Kaschina E. Cleaved high molecular weight kininogen, a novel factor in the regulation of matrix metalloproteinases in vascular smooth muscle cells. Biochem Pharmacol. 2010;79:172-179.
23. Qi Y, Li H, Shenoy V, Li Q, Wong F, Zhang L, Raizada MK, Sumners C, Katovich MJ. Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. Exp Physiol. 2012;97:89-101.
24. Jehle AB, Xu Y, Dimaria JM, French BA, Epstein FH, Berr SS, Roy RJ, Kemp BA, Carey RM, Kramer CM. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J Cardiovasc Pharmacol. 2012;59:363-368.
25. French BA, Kramer CM. Mechanisms of post-infarct left ventricular remodeling. Drug Discov Today Dis Mech. 2007;4:185-196.
26. Shimizu M, Kario K. Role of the augmentation index in hypertension. Ther Adv Cardiovasc Dis. 2008;2:25-35.
27. Voros S, Yang Z, Bove CM, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Conaway MR, Matsubara H, Carey RM, Kramer CM. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2006;290:H1004-H1010.
28. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schlüter KD, Boddddhm M. Alterations of beta-Adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 2002;283:H1253-H1262.
29. Khan R, Sheppard R. Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology. 2006;118:10-24.
30. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev. 2007;87:1285-1342.
31. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-Type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol. 2000;32:109-120.
32. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Escobar PG, Cleutjens JP, Smits JF, Daemen MJ, Zile MR, Spinale FG. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2003;284:H364-H371.
33. Jenkins G. The role of proteases in transforming growth factor-β activation. Int J Biochem Cell Biol. 2008;40:1068-1078.
34. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
35. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res. 2003;92:827-839.
36. Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, Geurts N, Thoddddne-Reineke C, Lucht K, Seidel K, Hallberg A, Dahloddddf B, Unger T, Hendrix S, Steckelings UM. AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis. 2013;51:177-191.